DailyIQ
|
Sector:HealthcareAll sectors
Last updatedUpdating…

ABBV·AbbVie Inc.

$271.31
+4.62 (+1.73%)
After Hours
High
$274.94
Open
$268.40
Market Cap
469.63B
52W High
$272.20
Low
$266.89
P. Close
$271.31
P/E
74.43
52W Low
$187.00
Fwd P/E
16.73
DailyIQ Est.
$293.27
Inst. Ownership
40.4%
Short Interest
1.13%
Days to Cover
4.5
Technical Score (1D)
91
BULLISH
News Sentiment
69
BULLISH
On Oct 7, AbbVie announced that the U.S. Food and Drug Administration granted two Breakthrough Therapy Designations for its investigational antibody‑drug conjugate telisotuzumab adizutecan, one for use with bevacizumab in refractory metastatic colorectal cancer and another for monotherapy in a specific subset of metastatic non‑small cell lung cancer patients, a decision that could accelerate the drug’s development path. On the same day, Morgan Stanley raised its price target for AbbVie to $310 from $296, citing stronger earnings guidance and a favorable pipeline outlook as the basis for the upgrade. Also on Oct 7, AbbVie reported that its bispecific antibody epcoritamab combined with R‑CHOP reduced the risk of disease progression or death by 51 % in a Phase 3 EPCORE DLBCL‑2 trial, the first evidence of a bispecific antibody providing a meaningful benefit in the frontline diffuse large B‑cell lymphoma setting. The trial’s hazard ratio of 0.49 and highly significant p‑value underscored the robustness of the data and suggested a major therapeutic advance for this aggressive lymphoma. These developments collectively highlighted AbbVie’s expanding antibody‑drug conjugate and bispecific antibody portfolios and the potential for accelerated regulatory review and broader clinical use.
LOW TARGET
$200 -26.3%
1 analysts
MEAN TARGET
$280 +3.3%
23 analysts
HIGH TARGET
$328 +20.9%
17 analysts
PRICE RANGE
$200.00 - $328.00
SB / B / H / S / SS
10/22/7/1/1
DAILYIQ EST.
$293.27 (+8.1%)
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYQ
Country
United States
Website
abbvie.com
Symbol
ABBV
Description
AbbVie is a global biopharmaceutical company focused on discovering and delivering innovative medicines. The company's core business centers on developing and commercializing a diverse portfolio of therapies, including treatments for autoimmune diseases like Humira and Skyrizi, and oncology drugs such as Imbruvica and Venclexta/Venclyxto. AbbVie also provides solutions for neuroscience conditions, encompassing treatments for schizophrenia, migraine, and Parkinson's disease. Furthermore, the company's offerings extend to eye care products and therapies for chronic hepatitis C virus infection and gastrointestinal disorders. Headquartered in North Chicago, Illinois, AbbVie's research-driven approach aims to address significant unmet medical needs across various therapeutic areas.
Bought (1Y)
0 shares
$0
Sold (1Y)
32,710 shares
$8.2M
RAPP EDWARD J-
Award/Grant129 shares2026-09-30
Quaggin Susan E-
Award/Grant59 shares2026-09-30
Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER
Option Exercise32,710 shares2026-08-14
Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER
Sell32,710 shares2026-08-14
Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER
Option Exercise32,710 shares2026-08-14
View full insider trading history →
61/ 100
Neutral / mixed
Overall: Neutral
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
70.2%
Net Margin
6.9%
Revenue CAGR
9.4%
Current Ratio
0.67x
Debt / Equity
-20.49x
Return on Equity
-129.2%
View full financials →
Earnings Summary
AbbVie is a global biopharmaceutical company focused on developing and commercializing a diverse portfolio of therapies, including autoimmune treatments such as Humira and Skyrizi, oncology drugs like Imbruvica, and neuroscience and eye care products. Operating within the healthcare sector’s drug manufacturers industry, AbbVie has historically leveraged its research-driven approach to address unmet medical needs across multiple therapeutic areas. In the most recent two quarters, Q3 2025 and Q4 2025, the company reported EPS of $1.86 and $2.71 respectively, both beating analyst expectations of $1.78 and $2.71, while revenue grew to $15.78 billion and $16.62 billion, a modest 2.5% increase from the prior year’s $15.49 billion and $15.52 billion. This contrasts with Q1 2025 and Q2 2025, where EPS of $0.24 and $1.03 fell short of estimates of $0.24 and $0.94, and revenue declined from $2.27 billion to $3.10 billion, reflecting a 7% YoY drop. Historically, AbbVie has maintained a steady YoY revenue growth trajectory, with a 3.4% increase in 2024 and a 2.5% rise in 2025, while EPS has shown a mixed pattern, beating estimates in 3 of the last 4 quarters but missing in Q1 2025. The company’s recent news highlights a successful transition from Humira, with Skyrizi and Rinvoq filling the revenue gap, and a 10.20% revenue increase reported on Oct 3, underscoring robust operating margins and strong cash flow.

EPS

EstBeatMiss
$1.48$2.14$2.81$3.47$4.14Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$3.83 - -
Q2'26$3.68$3.65-0.7%
Q1'26$3.74$2.65-29.2%
Q4'25$2.71$2.71+0.2%
Q3'25$1.78$1.86+4.2%
Q2'25$2.91$2.97+2.1%

Revenue

EstBeatMiss
$14.6B$15.5B$16.3B$17.2B$18.1BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$17.7B - -
Q2'26$17.1B$17.0B-0.6%
Q1'26$16.8B$15.0B-10.7%
Q4'25$16.7B$16.6B-0.8%
Q3'25 - $15.8B -
Q2'25 - $15.4B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ABBV Stock Snapshot

BULLISH91/100
$272.80+$1.49 (0.5%)
Market cap
469.63B
P/E ratio
74.4
Day range
$266.89 – $274.94
News sentiment
69/100 · Bullish
Analyst target
$280.29 (+2.7%)
Consensus
Buy · 41 analysts
52-week range+45.9% off low · +0.2% from high
$187.00$272.20
Price $272.80 DailyIQ Est. $293.27

ABBV's technical picture is constructive, with trend and momentum pointing the same direction. A stock this widely held moves on consensus revisions more than on individual catalysts.

Reverse DCF

What growth is priced into ABBV?

FAIR

At today's price, AbbVie Inc. needs to grow free cash flow about 10.8% a year for the next 10 years to justify its valuation at a 7.29% cost of capital. Over its actual history it has compounded free cash flow at 13.3% a year, so the market is asking for 2.6 percentage points below its own delivered rate. On that basis ABBV looks priced roughly in line with its own growth record.

Implied FCF growth
10.8%
Historical FCF CAGR
13.3%
Growth gap
-2.6 pts
Verdict
FAIR
Discount rate (WACC)
7.29%
Beta
0.52

Behaviour On Record

What ABBV's own history says about today's numbers

Realized volatility (21d)
17.3% 28th pct
Below its peak
-0.5%
vs 200-day average
+14.8%
Up days (1y)
48%

AbbVie Inc. is currently running 17.3% annualised volatility over the last 21 sessions. Measured against ABBV's own 13 years of daily returns rather than a market-wide average, that is the 28th percentile — on the quiet side for this stock, against a typical reading of 21.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

ABBV is at its running peak. Across 12 full years on file its median worst-drawdown-in-a-year was -20.9%, with the deepest at -36.0% in 2018 — so highs have historically been given back before they were extended.

Price sits +14.8% from its 200-day moving average. Against every other day in its history, that gap ranks at the 83rd percentile — a wider gap than this stock usually carries. Over the past year ABBV closed higher on 48% of sessions, and it is currently 2 sessions into a rising streak.

On October specifically: over 13 years of records, ABBV finished the month higher 7 of 13 times, with a median return of +3.1% and an average of -0.2%. Its strongest month historically has been November at +5.0% on average, its weakest January at -2.7%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: ABBV has opened more than 2% away from the prior close in 41 of 3,266 sessions (1.3% of the time), with the largest gaps running +6.3% and -4.5%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, ABBV moved an average of 2.9% in the session after earnings, closing higher 2 of those 3 times, with a median move of +1.7% and a largest of +4.6%.

All figures computed from 3,267 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against ABBV's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of ABBV's sector?

AbbVie Inc. sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging).

Sector rank
#3 of 12
Sector state
Lagging
Sector rotation score
64

Options Market

What is the options market pricing for ABBV?

CallsPuts

For AbbVie Inc.'s nearest expiry (2026-10-09, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.35), with at-the-money implied volatility around 49.8%. The options market is pricing roughly a ±3.1% move by that expiry — a range of about $254.96–$271.12.

Put/call ratio (2026-10-09)
0.35
ATM implied volatility
49.8%
Total open interest
7,272
Expected move by 2026-10-09
±3.1% ($254.96–$271.12)

Analyst Rating Changes

Are analysts turning bullish or bearish on ABBV?

Morgan Stanley most recently reiterated its rating on AbbVie Inc. to Overweight on Oct 7, 2026 with a price target of $310 (from $296). Over the last 90 days, coverage has run 2 upgrades against 0 downgrades, a net bullish lean.

Latest action
Morgan Stanley — Overweight
90-day upgrades
2
90-day downgrades
0
Net rating momentum
+2
DateFirmActionRatingPrice target
Oct 7, 2026Morgan StanleyMaintainedOverweight$296 → $310
Oct 6, 2026ScotiabankMaintainedSector Outperform$280 → $320
Sep 10, 2026HSBCMaintainedBuy$300 → $315
Aug 20, 2026Piper SandlerMaintainedOverweight$298 → $303
Aug 17, 2026Wells FargoMaintainedOverweight$295 → $300
Aug 13, 2026Wolfe ResearchUpgradePeer Perform → Outperform$300
Aug 11, 2026BNP ParibasMaintainedNeutral$218 → $247
Aug 10, 2026Evercore ISI GroupMaintainedOutperform$246 → $260
Aug 6, 2026BerenbergMaintainedBuy$275
Aug 5, 2026Erste GroupUpgradeHold → Buy-
Aug 4, 2026GuggenheimMaintainedBuy$261 → $288
Aug 3, 2026Canaccord GenuityMaintainedBuy$282 → $290

ABBV Competitive Positioning

AbbVie Inc. (ABBV) is tracked alongside these names in Drug Manufacturers - General on DailyIQ — ranked by market cap, with today's move alongside.

Held by These ETFs

ABBV is a top holding in these ETFs tracked on DailyIQ — bar length shows portfolio weight.

News Sentiment Analysis

Sentiment gathered from recent headlines

69/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
AbbVie (ABBV) saw its shares climb 2.3% on Wednesday after the U.S. Food and Drug Administration awarded two Breakthrough Therapy Designations to its experimental drug telisotuzumab adizutecan. One designation applies to the drug combined with bevacizumab for metastatic colorectal cancer patients who have exhausted standard therapies. The second designation covers telisotuzumab as a standalone treatment for advanced non‑small cell lung cancer patients with c‑Met‑positive tumors previously treated with platinum chemotherapy and anti‑PD‑(L)1 therapy. The designations were based on early results from the first‑in‑human M21‑404 study, signaling accelerated development and potential market entry for the drug. The FDA approvals are expected to enhance AbbVie’s oncology pipeline and could drive future revenue growth.
What did this article say?
Ironwood Pharmaceuticals reported that its flagship drug Linzess has seen robust prescription demand, partly due to a recent FDA approval expanding its use in pediatric patients. The company’s collaboration with AbbVie (ABBV) in the United States is a key driver of Linzess’ revenue, with both firms sharing profits and losses equally. The partnership is expected to support Ironwood’s third‑quarter earnings, and the expanded indications provide a new growth avenue for AbbVie’s commercial portfolio.
What did this article say?
AbbVie (ABBV) announced that the U.S. Food and Drug Administration granted two Breakthrough Therapy Designations for its drug telisotuzumab adizutecan. One designation applies to a combination with bevacizumab for refractory metastatic colorectal cancer patients who have exhausted standard therapies. The second designation covers telisotuzumab adizutecan as monotherapy for a specific subset of non‑small cell lung cancer patients previously treated with platinum chemotherapy and anti‑PD‑(L)1 antibodies. The designations were based largely on early clinical data from the first‑in‑human study M21‑404, potentially accelerating development and regulatory review.
What did this article say?
Morgan Stanley increased its price target for AbbVie to $310 from $296, reflecting a more optimistic view of the company’s prospects. The brokerage cited stronger earnings guidance and a favorable pipeline outlook as key reasons for the upgrade. The move aligns with AbbVie’s recent performance and positions the stock favorably among peers.
What did this article say?
AbbVie announced that the U.S. Food and Drug Administration granted two Breakthrough Therapy Designations for its investigational antibody‑drug conjugate, telisotuzumab adizutecan (Temab‑A). The designations cover Temab‑A in combination with bevacizumab for refractory metastatic colorectal cancer and as monotherapy for metastatic non‑small cell lung cancer. The approvals highlight the company’s expanding ADC portfolio and signal potential accelerated development and regulatory pathways for the drug.
What did this article say?
AbbVie and Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial, showing that epcoritamab combined with R-CHOP reduced the risk of disease progression or death by 51% in newly diagnosed diffuse large B‑cell lymphoma patients. The study is the first Phase 3 evidence of a bispecific antibody providing a meaningful benefit in the frontline DLBCL setting. The data improve progression‑free survival and represent a significant advance in treatment options for this aggressive lymphoma.
What did this article say?
AbbVie Inc. reported a payout ratio of 190.40%, indicating it distributes nearly twice its reported earnings. The company’s free cash flow of $16.87 billion supports the dividend, but the high ratio suggests a potential dividend cut or reliance on non‑profit cash sources. Operating margin stood at 40.04% while net margin was 9.80%, revealing significant cost components such as amortization and debt interest. The disparity between operating cash flow ($19.51 billion) and net income ($6.27 billion) highlights the impact of non‑cash expenses on profitability.
What did this article say?
AbbVie’s blood‑cancer drug epcoritamab combined with R‑CHOP cut the risk of disease progression or death by 51% in a late‑stage study of newly diagnosed diffuse large B‑cell lymphoma. The result, reported by Reuters, supports moving the therapy earlier in treatment and could broaden its commercial reach. The company and partner Genmab highlighted a hazard ratio of 0.49 and a highly significant p‑value, underscoring the robustness of the data. Investors reacted with a modest 0.3% uptick in the stock, reflecting confidence in the trial’s implications for future sales.
What did this article say?
The article lists three growth stocks recommended for October 2026, including AbbVie (ABBV). It notes AbbVie's share price movement of -0.06% and positions the company alongside Amazon and Netflix. The piece emphasizes the importance of fundamentals and cautions against overvalued growth picks. No material corporate action or earnings update for AbbVie is disclosed, so the recommendation reflects a mild, non‑material view. The overall tone is neutral with a slight positive slant toward AbbVie as a viable growth option.

Technical Analysis

Real-time indicators across multiple timeframes

91
BULLISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $168.84B combined position · 13 adding, 10 trimming, 2 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy180,779,69910.46%$41.31B2026-01-29
BlackRock, Inc.▼ Sell149,488,4128.65%$37.62B2026-08-07
JPMorgan Chase & Co▼ Sell48,482,2962.81%$12.33B2026-08-12
Geode Capital Management, LLC▲ Buy46,998,4332.72%$11.81B2026-08-12
Morgan Stanley▲ Buy38,901,0012.25%$9.79B2026-08-13
Capital Research Global Investors▼ Sell30,101,5511.74%$7.57B2026-08-12
Norges Bank▼ Sell25,554,5381.48%$6.43B2026-08-12
Bank of America Corp▼ Sell21,237,7641.23%$5.34B2026-08-14
FMR LLC (Fidelity)▼ Sell20,773,7861.20%$5.23B2026-08-13
Northern Trust Corp▼ Sell20,558,4471.19%$5.17B2026-08-13
Capital World Investors▲ Buy19,178,9661.11%$4.83B2026-08-12
Goldman Sachs Group Inc▲ Buy17,743,5301.03%$4.46B2026-08-14
Fisher Asset Management, LLC▲ Buy9,497,9700.55%$2.39B2026-08-04
Wells Fargo & Company▲ Buy9,352,5800.54%$2.35B2026-08-14
Invesco Ltd.▼ Sell7,114,7820.41%$1.79B2026-08-14
Susquehanna International Group, LLP▲ Buy6,885,9710.40%$1.73B2026-08-14
Citadel Advisors LLC• Hold6,561,6830.38%$1.65B2026-09-02
Janus Henderson Group plc• Hold6,931,0360.40%$1.51B2026-05-18
Wellington Management Group LLP▼ Sell5,055,5890.29%$1.27B2026-08-14
Citigroup Inc▲ Buy3,628,5070.21%$913.08M2026-08-03
AllianceBernstein L.P.▼ Sell4,092,3350.24%$890.04M2026-08-14
Marshall Wace, LLP▲ Buy2,990,5120.17%$752.53M2026-08-13
D. E. Shaw & Co., Inc.▲ Buy2,449,6160.14%$616.42M2026-08-14
Millennium Management LLC▲ Buy2,263,3750.13%$569.56M2026-08-14
AQR Capital Management LLC▲ Buy2,015,2380.12%$507.11M2026-08-14
Q2 2026 flow:14.20M sh bought ($3.57B)19.64M sh sold ($4.92B)net -5.44M sh (−$1.35B)
View full institutional holdings history →
Congressional Trading Activity
25 disclosed trades · ~$316.0K est. traded value · 10 buys, 15 sells
MemberChamberStateTypeAmountTradedFiled
Pete SessionsHouseTX17▼ Sell$15K - $50K2026-09-142026-09-18
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2026-05-052026-06-03
Alan ArmstrongSenateOK▲ Buy$15K - $50K2026-03-272026-07-21
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-12-182026-01-15
Julia LetlowHouseLA05▼ Sell$1K - $15K2025-12-082026-01-13
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-11-132025-12-11
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-312025-11-21
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-10-302025-11-21
John BoozmanSenateAR▼ Sell$1K - $15K2025-08-222025-09-12
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-08-142025-09-11
John BoozmanSenateAR▼ Sell$1K - $15K2025-08-112025-09-12
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-08-042025-08-15
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-07-222025-08-13
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-07-222025-08-13
Ritchie John TorresHouseNY15▼ Sell$1K - $15K2025-07-112025-08-20
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-06-172025-08-13
Josh GottheimerHouseNJ05▲ Buy$1K - $15K2025-05-222025-06-11
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-05-152025-06-09
Marjorie Taylor GreeneHouseGA14▲ Buy$1K - $15K2025-05-052025-05-06
Julia LetlowHouseLA05▲ Buy$1K - $15K2025-04-282026-01-13
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2025-04-172025-05-14
Jefferson ShreveHouseIN06▼ Sell$50K - $100K2025-04-172025-05-08
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-05-08
Jared MoskowitzHouseFL23▲ Buy$1K - $15K2025-04-072025-05-09
View full congressional trading history →

Discover More

TBXU
Direxion Daily Biotech Top 5 Bull 2X ETF
$36.64
+0.00%
APGE
Apogee Therapeutics Inc.
$135.11
+0.01%
JNJ
Johnson & Johnson
$258.25
-0.05%
BMY
Bristol-Myers Squibb Company
$59.50
-0.32%
BBIO
BridgeBio Pharma Inc.
$66.50
+0.05%
AXSM
Axsome Therapeutics Inc.
$172.97
+0.13%
VTRS
Viatris Inc.
$17.51
-0.06%
ELIL
Direxion Daily LLY Bull 2X Shares
$28.98
-0.34%
HALO
Halozyme Therapeutics Inc.
$110.79
-0.03%
ELAN
Elanco Animal Health Incorporated
$22.36
+0.00%